血清和肽素水平预测多发伤患者不良结局并改善TRISS与MGAP评分的风险预测:单中心前瞻性队列研究
这项单中心前瞻性队列研究纳入因潜在严重创伤就诊于急诊科的患者,检测血清和肽素水平,分析其与30天死亡率和需要重症监护管理的相关性。结果显示,30天内死亡患者和肽素中位数644.4 pg/L(四分位距[472.5, 785.9]),入住ICU患者233.8 pg/L([105.7, 366.4]),均高于存活者37.49 pg/L([17.88, 77.68])。将和肽素自然对数加入TRISS和MGAP模型后,TRISS的AUC从0.89提高到0.96,MGAP的AUC从0.82提高到0.95,Brier评分校准和净重分类改善或综合判别改善分析均显示显著改善。作者认为和肽素有望作为预测创伤结局的新型生物标志物。
要点
- 30天内死亡的多发伤患者入院和肽素中位数644.4 pg/L(IQR [472.5, 785.9]),高于存活者的37.49 pg/L(IQR [17.88, 77.68])。
- 入住ICU的多发伤患者和肽素中位数233.8 pg/L(IQR [105.7, 366.4]),高于存活者的37.49 pg/L(IQR [17.88, 77.68])。
- 将和肽素自然对数加入TRISS模型后,AUC从0.89提高到0.96;加入MGAP模型后,AUC从0.82提高到0.95。
- 和肽素增强模型的校准(Brier评分)和重分类(净重分类改善或综合判别改善)均较原模型显著改善。
- 作者认为和肽素有望作为预测创伤结局的新型生物标志物,并建立了基于网页的计算器以生成各模型的预测死亡率。
适用人群与场景
- 因潜在严重创伤就诊于急诊科的多发伤患者;单中心前瞻性队列研究纳入人群。
研究设计与关键结果
- 研究类型:单中心前瞻性队列研究;纳入因潜在严重创伤就诊于急诊科的患者,检测入院血清和肽素水平,分析其与30天死亡率和需要重症监护管理的相关性。
- 30天内死亡患者和肽素中位数644.4 pg/L(IQR [472.5, 785.9]),入住ICU患者233.8 pg/L(IQR [105.7, 366.4]),存活者37.49 pg/L(IQR [17.88, 77.68])。
- 将和肽素自然对数加入TRISS模型后,AUC从0.89提高到0.96;加入MGAP模型后,AUC从0.82提高到0.95。
- 以Brier评分衡量的校准和以净重分类改善或综合判别改善衡量的重分类分析均显示显著改善。
- 建立了基于网页的计算器,用于生成各模型的预测死亡率,便于临床使用。
证据类型、等级与局限
- 证据类型:单中心前瞻性队列研究;证据等级:预后与流行病学,Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为和肽素有望作为预测创伤结局的新型生物标志物;将和肽素与现有创伤严重度评分(TRISS或MGAP)联合可提高预测准确性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Multiple trauma deserves early prognostication and stratification. Copeptin, a precursor of vasopressin, is produced in response to stress. We examined the association between serum levels of copeptin and mortality risk in patients with multiple trauma. We aimed to also enhance the previously established Trauma-Related Injury Severity Score (TRISS) and Mechanism, GCS, Age, and Arterial Pressure (MGAP) score with the additional consideration of copeptin levels.
METHODS: This single-center prospective cohort study enrolled patients who presented to the emergency department with potential major injuries. The serum levels of copeptin were measured, and the correlation to clinical severity in terms of 30-day mortality and requirement of intensive care management was analyzed. By combining copeptin levels with TRISS or MGAP, comparison between performance of the original models with the copeptin-enhanced models was performed via discrimination, calibration, and reclassification analyses.
RESULTS: There was a significant increase in copeptin levels in patients who died within 30 days (median 644.4 pg/L, interquartile range [472.5, 785.9]) or were admitted to intensive care units (233.8 pg/L, [105.7, 366.4]), compared with those who survived (37.49 pg/L, [17.88, 77.68]). Adding the natural log of copeptin levels to the established TRISS and MGAP models improved the AUC of TRISS from 0.89 to 0.96, and that of MGAP from 0.82 to 0.95. Both calibrations as measured by Brier's scores and reclassification as measured by net reclassification improvement or integrated discrimination improvement demonstrated significant improvements. A Web-based calculator was built to generate predicted mortality rates of various models for convenient clinical use.
CONCLUSION: Admission serum copeptin levels were correlated with clinical severity in multiple trauma. Coupling copeptin with preexisting trauma severity scores improved prediction accuracy. Copeptin shows promise as a novel biomarker for the prediction of trauma outcome.
LEVEL OF EVIDENCE: Prognostic and Epidemiologic; Level III.
参考来源
- Hsein YC, Wu IJ, Tan J, et al. Serum levels of copeptin predict adverse outcomes and improve risk prediction of TRISS and MGAP scores in patients with multiple trauma: A single-center prospective cohort study. J Trauma Acute Care Surg. 2022. PMID: 36121260. doi:10.1097/TA.0000000000003793
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。